CAP

(ISC)² Issues Statement Reaffirming its Commitment to DEI in Response to Anti-DEI Legislation

Retrieved on: 
Monday, April 11, 2022
CISSP, LinkedIn, CBK, American Society of Association Executives, Organization, Leadership, (ISC)², Legislation, DEI, Association, Certification, ASAE, Workforce, School, SSCP, Software, Center, Industry, Twitter, ISC, CAP, Society, Time, Certified Information Systems Security Professional, Facebook, 2009 Davis Cup, Workplace, Education, CCSP, Medical device, Medicine, Property management

As the world's foremost cybersecurity professional organization, (ISC)is leading the charge to ensure our profession reflects the diversity of the world it serves.

Key Points: 
  • As the world's foremost cybersecurity professional organization, (ISC)is leading the charge to ensure our profession reflects the diversity of the world it serves.
  • For more information on DEI resources from (ISC), please visit: https://www.isc2.org/dei
    (ISC) is an international nonprofit membership association focused on inspiring a safe and secure cyber world.
  • Our vision is supported by our commitment to educate and reach the general public through our charitable foundation The Center for Cyber Safety and Education .
  • 2022 (ISC) Inc., (ISC), CISSP, SSCP, CCSP, CAP, CSSLP, HCISPP, CISSP-ISSAP, CISSP-ISSEP, CISSP-ISSMP and CBK are registered marks of (ISC), Inc.

Pangea Laboratory Donates 50,000 COVID-19 PCR Tests for the Uninsured

Retrieved on: 
Wednesday, April 6, 2022
CLIA, COO, College, Multimedia, PCR, Clinical Laboratory, EUA, Research, HRSA, CEO, COVID-19 testing, CORE (Community Organized Relief Effort), CAP, Emergency Use Authorization, COVID-19, Solution, HCA, CORE, Patient, Disease, Health Resources and Services Administration, Pharmaceutical industry, Hospital, Health insurance

TUSTIN, Calif., April 6, 2022 /PRNewswire/ -- Pangea Laboratory is donating 50,000 COVID-19 PCR tests, which have been made available for free to the uninsured in Los Angeles and Orange County. The donation, worth more than $5 million, was made possible with help from Zymo Research offering their Emergency Use Authorization (EUA) Quick SARS-CoV-2 rRT-PCR Kits at a discounted rate.

Key Points: 
  • The donation began on March 22, 2022, and Pangea Laboratory has since conducted more than 4000 free tests for those without health insurance.
  • "Our mission at Pangea Laboratory has always been to make quality healthcare more accessible and affordable," said Dr. Yap Ching Chew, COO of Pangea Laboratory.
  • Throughout the pandemic Pangea Laboratory has performed thousands of tests for the uninsured, many of whom are frontline workers or who run small businesses within our community.
  • Founded in 2014, Pangea Laboratory is a Clinical Laboratory Improvement Amendments (CLIA) certified and College of American Pathologists (CAP) accredited clinical laboratory.

aeSolutions to Present and Exhibit at AIChE 2022 Spring Meeting and 18th Global Congress on Process Safety

Retrieved on: 
Tuesday, April 5, 2022
Technology, Professional Services, Other Manufacturing, Textiles, Packaging, Engineering, Security, Automotive Manufacturing, Training, Manufacturing, Software, Networks, Education, Other Professional Services, Electronic Design Automation, Data Management, Consulting, CSP, Congress, Process, GCPS, American Institute of Chemical Engineers, PSM, Transience, PMP, Industry, Safety, SC, CAP, International, Process safety, CCPS, CFSE, Chemical substance, System, Engineering, Risk management

aeSolutions , a consulting, engineering and systems integration company that provides industrial process safety and automation products and services, today announced that the company will be presenting and exhibiting at the AIChE 2022 Spring Meeting and 18th Global Congress on Process Safety (GCPS) .

Key Points: 
  • aeSolutions , a consulting, engineering and systems integration company that provides industrial process safety and automation products and services, today announced that the company will be presenting and exhibiting at the AIChE 2022 Spring Meeting and 18th Global Congress on Process Safety (GCPS) .
  • The annual AIChE Spring Meeting and GCPS is the key technical conference for practicing chemical and process safety engineers, and covers the industry's critical needs more broadly and in-depth than any other industry conference.
  • In attendance from aeSolutions will be Vice President of Process Safety Laura Ankrom, PE; Process Safety Group Manager Don Connolley, CSP; Senior Director, Lifecycle Solutions, Jim Garrison, PE (SC), CAP, CFSE; Process Safety Engineer Dave Grattan PE, CFSE; and Senior Director, Fire Equipment Program, Chris Neff, PMP.
  • Process Safety Group Manager Don Connelly will co-chair three sessions: Proactive Process Safety; Featured CCPS Projects: Emerging Topics, Tools, and References; and Tutorials in Center for Chemical Process Safety (CCPS) International Conference.

Castle Biosciences to Acquire AltheaDx

Retrieved on: 
Monday, April 4, 2022
Mental Health, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, Company, Risk, TAM, LinkedIn, Mental health, Forward-looking statement, Growth, New York State Department of Health, SEC, Standard of care, Webcast, Uveal melanoma, Achievement, Health, Precision medicine, Skin, Investor relations, Securities Exchange Act of 1934, CAP, Twitter, DecisionDx-UM, Securities Act of 1933, Nasdaq, COVID-19, Physician, Randomized controlled trial, Selective serotonin reuptake inhibitor, Medicare, Employee Retirement Income Security Act of 1974, Anxiety, Solution, Depression, Annual report, Instagram, Atopic dermatitis, Acquisition, Patient, Pharmaceutical industry, Video game, Medical device, List of life sciences, Facebook, ALTHEADX AND IDGENETIX, CASTLE BIOSCIENCES

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire AltheaDx, Inc. (AltheaDx).

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire AltheaDx, Inc. (AltheaDx).
  • Castle Biosciences has strong expertise in providing advanced tests that improve health and guide patient care, and we are excited to join the team, said David Nikodem, Ph.D., chief executive officer of AltheaDx.
  • Under the terms of the definitive agreement, AltheaDx will become a wholly owned subsidiary of Castle Biosciences.
  • Upon closing of the transaction, the executive management team and other AltheaDx staff are expected to stay with Castle.

Caesar Finance Delivers APY Over 150,000%, Releases New Roadmap, Automated Staking, New Website, Unique Taxation And Protocol Utility

Retrieved on: 
Monday, April 4, 2022
Decentralized finance, Marketing, APY, Program, Health, Twitter, CAP, Time, Cryptocurrency, Catering, Titano

Caesar Finance built an automated staking system, Caesar Auto-Staking Protocol or CAP, that makes it easy to earn more tokens.

Key Points: 
  • Caesar Finance built an automated staking system, Caesar Auto-Staking Protocol or CAP, that makes it easy to earn more tokens.
  • One of the unique features of Caesar is the buy and sell fees.
  • Users buying and selling $CAESAR pay a fee that is redirected to fill the Caesar treasury.
  • $CAESAR Lockup will allow token holders to lock up their $CAESAR for a set period of time for a higher APY.

AnPac Bio Filed Request for a Hearing Regarding Continued Listing on NASDAQ, The Hearing was Granted and scheduled for Late April

Retrieved on: 
Monday, April 4, 2022
Listing Rules, Hearing, Company, Risk, CLIA, CDA, Letter, Compliance, Failure, U.S. Securities and Exchange Commission, Frost & Sullivan, American depositary receipt, Calendar, CAP, GLOBE, Frost, Security (finance), Online gambling, Dietary supplement, Nasdaq

On March 31, 2022, the Company filed a request for an appeal hearing before a Nasdaq Hearings Panel to present its plan to regain compliance with the applicable listing requirements of Nasdaq.

Key Points: 
  • On March 31, 2022, the Company filed a request for an appeal hearing before a Nasdaq Hearings Panel to present its plan to regain compliance with the applicable listing requirements of Nasdaq.
  • The Letter also indicated that the Company has not met the minimum standard requirements of $10,000,000 in stockholders equity, $50,000,000 in total assets and $50,000,000 in total revenue.
  • The Company will be notified if Nasdaq identifies new deficiencies either before or after the hearing, and will be provided an opportunity to respond.
  • AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 150 issued patents as of September 30, 2021.

CAP Consumer Survey Shows the Benefits of Site Blocking

Retrieved on: 
Wednesday, March 23, 2022
Association, Industry, Awareness, AVIA, General manager, Social media, CAP, Ecosystem, YouGov, Online shopping, Video game, Cryptocurrency

Over 40% of consumers in key markets across Southeast Asia have stopped or rarely access pirate services as a result of site blocking.

Key Points: 
  • Over 40% of consumers in key markets across Southeast Asia have stopped or rarely access pirate services as a result of site blocking.
  • Countries around the region that implement site-blocking showed a change in consumer behaviour to stop accessing piracy services due to sites being blocked and the change was most notable in those countries that used regulatory blocking.
  • Matthew Cheetham, General Manager of CAP, noted, "It is now clearly evident that site blocking, particularly regulatory blocking, is effective.
  • "However, the surveys also show the benefits of consumer education with a growing awareness amongst consumers of the negative consequences of piracy, most particularly via illicit profiteering and malware," added Cheetham.

Gravity Diagnostics Honored as a Fastest Growing Company in Cincinnati

Retrieved on: 
Thursday, March 31, 2022
CLIA, COO, Greater, Hospital Insurance and Diagnostic Services Act, Growth, Toxicology, Fortune 500, CEO, Achievement, Quality of life, CAP, American City Business Journals, GLOBE, Blood, COVID, Founder, Pharmaceutical industry, Gravity

Covington, March 31, 2022 (GLOBE NEWSWIRE) -- For the second year in a row, Gravity Diagnostics has been chosen as a 2022 Fast 55 finalist by the Cincinnati Business Courier.

Key Points: 
  • Covington, March 31, 2022 (GLOBE NEWSWIRE) -- For the second year in a row, Gravity Diagnostics has been chosen as a 2022 Fast 55 finalist by the Cincinnati Business Courier.
  • The Fast 55 Award is an achievement granted to privately held companies in the region that have seen the fastest growth within the last year.
  • Last year, Gravity took home the title of the fastest-growing company, having had the highest rate of growth at 2,767%.
  • Gravity Diagnostics is a CAP-accredited CLIA certified laboratory that offers testing in the areas ofCOVID-19, upper respiratory, toxicology, pharmacogenomics, sexually transmitted infectious, and Blood.

Sigyn Therapeutics Appoints Ajay Verma, M.D., Ph.D. to its Scientific Advisory Board

Retrieved on: 
Thursday, March 31, 2022
Company, Drug development, Therapy, Biomarker, Walter Reed Army Medical Center neglect scandal, OTC Markets Group, Outline of health sciences, Johns Hopkins University, EVP, Neurology, Community-acquired pneumonia, Death, Neurodegeneration, Hepatic encephalopathy, CMO, Inflammation, Risk, Biogen, Coronavirus Scientific Advisory Board (Turkey), Novartis, U.S. Securities and Exchange Commission, Security (finance), Walter Reed Army Medical Center, Sepsis, Technology, Exosome, CAP, Securities Exchange Act of 1934, Septic shock, Uniformed Services University of the Health Sciences, Securities Act of 1933, CA, GLOBE, Infection, VP, History of the University of Maryland, College Park, Medical research, SAN, Annual report, University, Merck, Pharmaceutical industry, Zoology, Research, Sutro Biopharma

His extensive clinical experience and resulting insights are anticipated to contribute to the continued advancement of Sigyn Therapy.

Key Points: 
  • His extensive clinical experience and resulting insights are anticipated to contribute to the continued advancement of Sigyn Therapy.
  • Sigyn Therapy is an extracorporeal blood purification technology being advanced to treat life-threatening inflammatory disorders.
  • Dr. Verma most recently headed R&D efforts at Yumanity Therapeutics, developing drugs against novel targets for treating neurodegenerative diseases.
  • This information in this press release contains forward-looking statements of Sigyn Therapeutics, Inc. (Sigyn) that involve substantial risks and uncertainties.

OraSure Technologies’ Subsidiary Diversigen Launches Metatranscriptomic Sequencing and Analysis Services for Gut Microbiome Samples

Retrieved on: 
Thursday, March 31, 2022
Company, Risk, OraSure Technologies, CLIA, Informatics, NASDAQ, Patent, Gene expression, Government, Forward-looking statement, Korea Disease Control and Prevention Agency, Disagreement, Public health, Coronavirus, Diet, Research, SEC, Hospital, Health, Food, COVID-19 testing, Technology, Database, CAP, RNA transfection, Metagenomics, Ageing, COVID-19, Intellectual property, Regulation of tobacco by the U.S. Food and Drug Administration, GLOBE, Algorithm, Center, Solution, Uncertainty, Annual report, Collection, Fine chemical, Risk management

BETHLEHEM, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that its Diversigen subsidiary has launched a new service to provide metatranscriptomic sequencing and analysis of gut microbiome samples.

Key Points: 
  • BETHLEHEM, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that its Diversigen subsidiary has launched a new service to provide metatranscriptomic sequencing and analysis of gut microbiome samples.
  • OraSure, together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, and Novosanis, provides its customers with end-to-end solutions that encompass tools, services and diagnostics.
  • Diversigen, Inc. is a subsidiary of OraSure Technologies Inc. Diversigen and CoreBiome, Inc. (also an OraSure subsidiary), came together to create one company under the Diversigen brand that is powering microbiome discovery through sequencing, analysis, and consulting services geared toward the study of the microbiome of living organisms and environments.
  • Diversigen provides consultative end-to-end solutions for sequencing, bioinformatics, and statistical analysis for the study of the microbiome of living organisms and environments.